

RECEIVED

NOV 08 2002

GP/1623

TECH CENTER 1600/2900

Practitioner's Docket No. MPI00-521P1RM

PATENT

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Rajasekhar Bandaru		
Application No.:	10/024,036	Group No.:	1623
Filed:	December 17, 2001	Examiner:	
For:	68730 AND 69112 PROTEIN KINASE MOLECULES AND USES THEREFOR		

Commissioner for Patents  
Washington, D.C. 20231

## TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING  
INFORMATION DISCLOSURE STATEMENT

The information disclosure statement submitted herewith is being filed:

☒ Within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. section 1.97(b).

OR

☐ *After* three months of the filing date of this national application or the date of entry of the national stage as set forth in Section 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last but *before* the mailing date of either:

## CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\*

I hereby certify that, on the date shown below, this correspondence is being:

## MAILING

☒ deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10\*

☒ with sufficient postage as first class mail.

☐ as "Express Mail Post Office to Address"  
Mailing Label No.

## TRANSMISSION

☐ transmitted by facsimile to the Patent and Trademark Office.

Signature

Date: November 4, 2002Mary MacKinnon

(type or print name of person certifying)

**\*WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will *not* be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

- (1) a final action under Section 1.113,
- (2) a notice of allowance under Section 1.311, or
- (3) an action that otherwise closes prosecution in the application

whichever occurs first.

☐ Accompanying this transmittal is the fee set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c). (\$180.00).

☐ Each item of the information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(1).

☐ No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the statement after making reasonable inquiry, was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(2).

OR

☐ The information disclosure statement transmitted herewith is being filed *after* a final action under Section 1.113, or a notice of allowance under Section 1.311, whichever occurs first, but before, or simultaneously with, the payment of the issue fee.

☐ In accordance with the requirements of 37 C.F.R. Section 1.97(d):

A. ☐ Accompanying this transmittal is the fee set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c). (\$180.00).

B. ☐ Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(1).

C. ☐ No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the statement after making reasonable inquiry, was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(2).

Practitioner's Docket No. MPI00-521P1RM

Application No. 10/024,036

**FEE PAYMENT**


3. ☐ The fee due is set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c) (\$180.00).

☒ Applicant believes no fee is due in connection with this submission.

	Fee due	\$0.00
<b>METHOD OF PAYMENT OF FEE</b>		
4. <input type="checkbox"/> Attached is a check in the amount of \$ _____.		
<input type="checkbox"/> Charge Account No. 501668 in the amount of	\$0.00	.

☐ A duplicate of this request is attached.

If any additional fees are due, please charge Account 501668.

<u>November 4, 2002</u>	MILLENNIUM PHARMACEUTICALS, INC. By <u></u> Paul J. Paglierani Registration No. P-52,498 75 Sidney Street Cambridge, MA 02139 Telephone - 617-761-6865 Facsimile - 617-551-8820
-------------------------	---



RECEIVED

NOV 08 2002

Patitioner's Docket No. MPI00-521P1RM

TECH CENTER 1600/2900

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Rajasekhar Bandaru

Application No.: 10/024,036

Group No.: 1623

Filed: December 17, 2001

Examiner:

For: 68730 AND 69112 PROTEIN KINASE MOLECULES AND USES THEREFOR

Commissioner for Patents  
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

List of Sections Forming Part of This Information Disclosure Statement

The following sections are being submitted for this Information Disclosure Statement:

1. ☒ Preliminary Statements
2. ☒ Forms PTO/SB/08A and 08B (substitute for Form PTO-1449)
3. ☒ Identification of Person(s) Making This Information Disclosure Statement

Section 1. Preliminary statements

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☒ deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10\*

- ☒ with sufficient postage as first class mail.

☐ as "Express Mail Post Office to Address"  
Mailing Label No.

TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office.

Signature

*Mary MacKinnon*

Date: November 4, 2002

Mary MacKinnon  
(type or print name of person certifying)

**\*WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Practitioner's Docket No. MPI00-521P1RM

Application No. 10/024,036

search has been made (37 C.F.R. section 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

**Section 2. Copies of Listed Information Items Accompanying This Statement**

Legible copies of all items listed in Forms PTO/SB/08A and 08B (substitute for Form PTO-1449) accompany this information statement.

*(complete the following, if applicable)*

- ☐ Exception(s) to above:
- ☐ Items in prior application, from which an earlier filing date is claimed for this application, as identified in Section 4.
- ☐ Cumulative patents or publications identified in Section 5.

**Section 3. Identification of Person(s) Making This Information Disclosure Statement**

November 4, 2002

MILLENNIUM PHARMACEUTICALS, INC.

By Paul J. Paglierani

Paul J. Paglierani  
Registration No. P-52,498  
75 Sidney Street  
Cambridge, MA 02139  
Telephone - 617-761-6865  
Facsimile - 617-551-8820

Please type a plus sign (+) inside this box → ☐

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

## Complete if Known

Application Number 10/024,036  
Filing Date December 17, 2001  
First Named Inventor Rajasekhar Bandaru  
Group Art Unit 1623  
Examiner Name  
Attorney Docket Number MPI00-521P1RM

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document Kind Code <sup>2</sup> Number (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document (MM-DD-YYYY)	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1				

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Office <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document (MM-DD-YYYY)	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	B1	WO 01/53312 A1	HYSEQ, Inc.	07/26/2001	Title pages, 1-105, 108, 113, 122, 130-132, 140-143, 164, 220, 255, 284, 300, 464-465, 604-607, Search Report	
	B2	WO 01/38503 A2	Sugen, Inc.	05/31/2001	Title pages, 1-110, 112, 121, 123, 131-132, 140, 143, 153, 157-388, Figures 1G and 2C, Search Report	
	B3	WO 01/42435 A2	Lexicon Genetics, Inc.	06/14/2001	Title pages, 1-26, Sequence Listing pages 1-4, Search Report	
	B4	WO 01/81555 A2	Incyte Genomics, Inc.	11/01/2001	Title pages, 1-118, Sequence Listing pages 1-46	
	B5	WO 00/73468 A1	Immunex Corporation	12/07/2000	Title page, 1-77, Figure 3, Sequence Listing pages 1-2, 8-10, Search Report	
	B6	WO 00/06728 A2	Incyte Pharmaceuticals, Inc.	02/10/2000	Title pages, 1-76, Sequence Listing pages 1-64, Search Report	
	B7	WO 00/73469 A2	Sugen, Inc.	07/12/2000	Title page, 1-161, Figure 1F, Figure 2R, Figure 2S, Search Report	
	B8	WO 01/90304 A2	Human Genome Sciences, Inc.	11/29/2001	Title page, 1-21, 1090-1091, 1141-1150, 1675, 1739-2080	
	B9	WO 02/33099 A2	Incyte Genomics, Inc.	04/25/2002	Title page, 1-134, Sequence Listing pages 1-75	
	B10	WO 02/070678 A2	Bayer Aktiengesellschaft	09/12/2002	Title page, 1-108, Figures 1-21, Sequence Listing pages 1-20	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation design number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

NOV 08 2002

RECEIVED

TECH CENTER 1600/2900



Please type a plus sign (+) inside this box → ☐ + .

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

RECEIVED

NOV 08 2002

TECH CENTER 1600/2900

<b>Substitute for form 1449B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	10/024,036
				<b>Filing Date</b>	December 17, 2001
				<b>First Named Inventor</b>	Rajasekhar Bandaru
				<b>Group Art Unit</b>	1623
				<b>Examiner Name</b>	
<b>Sheet</b>	1	<b>of</b>	1	<b>Attorney Docket Number</b>	MPI00-521P1RM

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T <sup>2</sup>
	C1	Verploegen, Sandra, et al.: "Identification and Characterization of CKLiK, a Novel Granulocyte Ca++/calmodulin-dependent Kinase", The American Society of Hematology, The Department of Pulmonary Diseases, University Medical Centre Utrecht, The Netherlands, November 1, 2000, Volume 96, Number 9	
	C2	Nagase, Takahiro, et al.: "Prediction of the Coding Sequences of Unidentified Human Genes. XIX. The Complete Sequences of 100 New cDNA Clones from Brain Which Code for Large Proteins in vitro" Kazusa DNA Research Institute 7, 347-355 (2000), Advanced Engineering Center, RIKEN (The Institute of Physical and Chemical Research), 2-1, Hirose, Wako, Saitama 351-0918, Japan	

<b>Examiner Signature</b>		<b>Date Considered</b>	
-------------------------------	--	----------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation design number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.